Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Endocrine Disorders
Published in: BMC Endocrine Disorders 1/2021

01-12-2021 | Obesity | Research article

Dynamic behavior of metabolic syndrome progression: a comprehensive systematic review on recent discoveries

Authors: Pezhman Bagheri, Davood Khalili, Mozhgan Seif, Abbas Rezaianzadeh

Published in: BMC Endocrine Disorders | Issue 1/2021

Login to get access

Abstract

Background

The assessment of the natural history of metabolic syndrome (MetS) has an important role in clarifying the pathways of this disorder.

Objective

This study purposed to provide a rational statistical view of MetS progression pathway.

Methods

We performed a systematic review in accordance with the PRISMA Statement until September 2019 in the Medline/PubMed, Scopus, Embase, Web of Science and Google Scholar databases. From the 68 found studies, 12 studies were eligible for review finally.

Results

The selected studies were divided in 2 groups with Markovian and non-Markovian approach. With the Markov approach, the most important trigger for the MetS chain was dyslipidemia with overweight/obesity in the under-50 and with hypertension in the over-50 age group, where overweight/obesity was more important in women and hypertension in men. In non-Markov approach, the most common trigger was hypertension. Transition probability (TP) from no component to MetS were higher in all Markovian studies in men than in women. In the Markovians the combination of dyslipidemia with overweight/obesity and in non-Markovians, hyperglycemia with overweight/obesity were the most common combinations. Finally, the most important components, which predict the MetS, were 2-component states and hyperglycemia in Markovian approach and overweight/obesity in non-Markovians.

Conclusions

Among the components of the MetS, dyslipidemia and hypertension seems to be the main developer components in natural history of the MetS. Also, in this chain, the most likely combination over time that determines the future status of people seems to be the combination of dyslipidemia with obesity or hyperglycemia. However, more research is needed.
Appendix
Available only for authorised users
Literature
1.
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; world heart federation; international atherosclerosis society; and International Association for the Study of obesity. Circulation. 2009;120(16):1640–5.PubMedCrossRef
2.
Tran BT, Jeong BY, Oh J-K. The prevalence trend of metabolic syndrome and its components and risk factors in Korean adults: results from the Korean National Health and Nutrition Examination Survey 2008–2013. BMC Public Health. 2017;17(1):71.PubMedPubMedCentralCrossRef
3.
Slagter SN, Waateringe RP, APV B, Klauw MM, BHR W, Vliet-Ostaptchouk JV. BMI and age differences in metabolic syndrome: the Dutch Lifelines Cohort Study. Sex. 2017;6(4):278.
4.
Schwarz PEH, Reimann M, Li J, Bergmann A, Licinio J, Wong ML, et al. The metabolic syndrome - a global challenge for prevention. Horm Metab Res. 2007;39(11):777–80.PubMedCrossRef
5.
Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. Jama. 2002;288(21):2709–16.PubMedCrossRef
6.
Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Giugliano D. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine. 2014;45(1):28–36.PubMedCrossRef
7.
Sung KC, Ryu S, Reaven GM. Relationship between obesity and several cardiovascular disease risk factors in apparently healthy Korean individuals: comparison of body mass index and waist circumference. Metab Clin Exp. 2007;56(3):297–303.PubMedCrossRef
8.
Li NY, Yu J, Zhang XW, Wang SX, Chang P, Ding Q, et al. Features of left ventricular hypertrophy in patients with metabolic syndrome with or without comparable blood pressure: a meta-analysis. Endocrine. 2013;43(3):548–63.PubMedCrossRef
9.
Ford ES, Li C. Defining the metabolic syndrome in children and adolescents: will the real definition please stand up? J Pediatr. 2008;152(2):160–4.PubMedCrossRef
10.
Athyros VG, Ganotakis ES, Elisaf M, Mikhailidis DP. The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and international diabetes federation definitions. Curr Med Res Opin. 2005;21(8):1157–9.PubMedCrossRef
11.
Carnethon MR, Loria CM, Hill JO, Sidney S, Savage PJ, Liu K. Risk factors for the metabolic syndrome: the coronary artery risk development in young adults (CARDIA) study, 1985-2001. Diabetes Care. 2004;27(11):2707–15.PubMedCrossRef
12.
Zuo H, Shi Z, Hu X, Wu M, Guo Z, Hussain A. Prevalence of metabolic syndrome and factors associated with its components in Chinese adults. Metab Clin Exp. 2009;58:1102–8.PubMedCrossRef
13.
Santos AC, Severo M, Barros H. Incidence and risk factors for the metabolic syndrome in an urban south European population. Prev Med. 2010;50(3):99–105.PubMedCrossRef
14.
Liese AD, Mayer-Davis EJ, Haffner SM. Development of the multiple metabolic syndrome: an epidemiologic perspective. Epidemiol Rev. 1998;20(2):157–72.PubMedCrossRef
15.
16.
Chen X, Chen Q, Chen L, Zhang P, Xiao J, Wang S. Description and prediction of the development of metabolic syndrome in Dongying City: a longitudinal analysis using the Markov model. BMC Public Health. 2014;14:1033.PubMedPubMedCentralCrossRef
17.
Scuteri A, Morrell CH, Najjar SS, Muller D, Andres R, Ferrucci L, et al. Longitudinal paths to the metabolic syndrome: can the incidence of the metabolic syndrome be predicted? The Baltimore longitudinal study of aging. J Gerontol A Biol Sci Med Sci. 2009;64(5):590–8.PubMedCrossRef
18.
Cheung BM, Wat NM, Tam S, Thomas GN, Leung GM, Cheng CH, et al. Components of the metabolic syndrome predictive of its development: a 6-year longitudinal study in Hong Kong Chinese. Clin Endocrinol. 2008;68(5):730–7.CrossRef
19.
Jia X, Chen Q, Wu P, Liu M, Chen X, Xiao J, et al. Dynamic development of metabolic syndrome and its risk prediction in Chinese population: a longitudinal study using Markov model. Diabetology & metabolic syndrome. 2018;10:24.CrossRef
20.
Tao LX, Wang W, Zhu HP, Huo D, Zhou T, Pan L, et al. Risk profiles for metabolic syndrome and its transition patterns for the elderly in Beijing, 1992-2009. Endocrine. 2014;47(1):161–8.PubMedCrossRef
21.
Hwang LC, Bai CH, You SL, Sun CA, Chen CJ. Description and prediction of the development of metabolic syndrome: a longitudinal analysis using a markov model approach. PLoS One. 2013;8(6):e67436.PubMedPubMedCentralCrossRef
22.
Harati H, Hadaegh F, Momenan AA, Ghanei L, Bozorgmanesh MR, Ghanbarian A, et al. Reduction in incidence of type 2 diabetes by lifestyle intervention in a middle eastern community. Am J Prevent Med. 2010;38(6):628–36 e1.CrossRef
23.
24.
Tang X, Liu Q. Prediction of the development of metabolic syndrome by the Markov model based on a longitudinal study in Dalian City. BMC Public Health. 2018;18(1):707.PubMedPubMedCentralCrossRef
25.
Haring R, Rosvall M, Volker U, Volzke H, Kroemer H, Nauck M, et al. A network-based approach to visualize prevalence and progression of metabolic syndrome components. PLoS One. 2012;7(6):e39461.PubMedPubMedCentralCrossRef
26.
Barcelo MA, Rodriguez-Poncelas A, Saez M, Coll-de-Tuero G. The dynamic behaviour of metabolic syndrome and its components in an eight-year population-based cohort from the Mediterranean. PLoS One. 2017;12(5):e0176665.PubMedPubMedCentralCrossRef
27.
DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14(3):173–94.PubMedCrossRef
28.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.PubMedPubMedCentralCrossRef
29.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.CrossRefPubMed
30.
Patel PA, Scott CG, Rodeheffer RJ, Chen HH. The natural history of patients with isolated metabolic syndrome. Mayo Clin Proc. 2016;91(5):623–33.PubMedCrossRef
31.
Franco OH, Massaro JM, Civil J, Cobain MR, O'Malley B, D'Agostino RB Sr. Trajectories of entering the metabolic syndrome: the Framingham heart study. Circulation. 2009;120(20):1943–50.PubMedCrossRef
32.
Morrison JA, Friedman LA, Harlan WR, Harlan LC, Barton BA, Schreiber GB, et al. Development of the metabolic syndrome in black and white adolescent girls: a longitudinal assessment. Pediatrics. 2005;116(5):1178–82.PubMedCrossRef
33.
Stroock DW. An introduction to Markov processes. Cambridge: Springer; 2005.
34.
Andersen PK, Keiding N. Multi-state models for event history analysis. Stat Methods Med Res. 2002;11(2):91–115.PubMedCrossRef
35.
Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Mak. 1983;3(4):419–58.CrossRef
36.
37.
Teede HJ, Lombard C, Deeks AA. Obesity, metabolic complications and the menopause: an opportunity for prevention. Climacteric : the journal of the International Menopause Society. 2010;13(3):203–9.CrossRef
38.
Wu SI, Chou P, Tsai ST. The impact of years since menopause on the development of impaired glucose tolerance. J Clin Epidemiol. 2001;54(2):117–20.PubMedCrossRef
39.
Tomlinson JW, Finney J, Gay C, Hughes BA, Hughes SV, Stewart PM. Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity. Diabetes. 2008;57(10):2652–60.PubMedPubMedCentralCrossRef
40.
Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis. 2017;11(8):215–25.PubMedPubMedCentralCrossRef
41.
42.
Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Investig. 2002;32(Suppl 3):14–23.CrossRef
43.
Chedraui P, Escobar GS, Pérez-López FR, Palla G, Montt-Guevara M, Cecchi E, et al. Angiogenesis, inflammation and endothelial function in postmenopausal women screened for the metabolic syndrome. Maturitas. 2014;77(4):370–4.PubMedCrossRef
44.
45.
Tenenbaum A, Fisman EZ. “The metabolic syndrome... is dead”: These reports are an exaggeration. Cardiovascular Diabetol. 2011;10(1):11.CrossRef
46.
Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev. 2007;87(2):507–20.PubMedCrossRef
47.
Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–97.CrossRef
48.
Ortega Francisco B, Lavie Carl J, Blair SN. Obesity and cardiovascular disease. Circ Res. 2016;118(11):1752–70.PubMedCrossRef
49.
50.
Halpern A, Mancini MC. Treatment of obesity: an update on anti-obesity medications. Obesity Rev. 2003;4(1):25–42.CrossRef
51.
Sarebanhassanabadi M, Jalil Mirhosseini S, Mirzaei M, Namayandeh SM, Soltani MH, Pedarzadeh A, et al. The incidence of metabolic syndrome and the Most powerful components as predictors of metabolic syndrome in Central Iran: a 10-year follow-up in a cohort study. Iran Red Crescent Med J. 2017;19(7):e14934.CrossRef
52.
53.
Herningtyas EH, Ng TS. Prevalence and distribution of metabolic syndrome and its components among provinces and ethnic groups in Indonesia. BMC Public Health. 2019;19(1):377.PubMedPubMedCentralCrossRef
54.
Osei-Yeboah J, Owiredu WKBA, Norgbe GK, Yao Lokpo S, Gyamfi J, Alote Allotey E, et al. The Prevalence of Metabolic Syndrome and Its Components among People with Type 2 Diabetes in the Ho Municipality, Ghana: A Cross-Sectional Study. Int J Chronic Dis. 2017;2017:8765804.PubMedPubMedCentral
55.
Marbou W, Kuete V. Prevalence of metabolic syndrome and its components in Bamboutos Division’s adults, West Region of Cameroon. BioMed Res Int. 2019;2019:1–12.CrossRef
56.
Erem C, Hacihasanoglu A, Deger O, Kocak M, Topbas M. Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study. Endocrine. 2008;34(1):36–51.PubMedCrossRef
57.
Wang S, Xu L, Jonas JB, You QS, Wang YX, Yang H. Prevalence and associated factors of dyslipidemia in the adult Chinese population. PLoS One. 2011;6(3):e17326.PubMedPubMedCentralCrossRef
58.
Khosravi A, Akhavan Tabib A, Golshadi I, Dana Siadat Z, Bahonar A, Zarfeshani S, et al. The relationship between weight and CVD risk factors in a sample population from Central Iran (based on IHHP). ARYA Atheroscler. 2012;8(2):82–9.PubMedPubMedCentral
59.
Park HS, Yun YS, Park JY, Kim YS, Choi JM. Obesity, abdominal obesity, and clustering of cardiovascular risk factors in South Korea. Asia Pac J Clin Nutr. 2003;12(4):411–8.PubMed
60.
61.
Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl. 2009;30(6):726–33.PubMedCrossRef
62.
Kaukua J, Pekkarinen T, Sane T, Mustajoki P. Sex hormones and sexual function in obese men losing weight. Obes Res. 2003;11(6):689–94.PubMedCrossRef
63.
Corona G, Rastrelli G, Monami M, Saad F, Luconi M, Lucchese M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol. 2013;168(6):829–43.PubMedCrossRef
64.
Wang H, Liu A, Zhou Y, Xiao Y, Yan Y, Zhao T, et al. The correlation between serum free thyroxine and regression of dyslipidemia in adult males: A 4.5-year prospective study. Medicine. 2017;96(39):e8163.PubMedPubMedCentralCrossRef
65.
Rizos CV, Elisaf MS, Liberopoulos EN. Effects of thyroid dysfunction on lipid profile. Open Cardiovascular Med J. 2011;5:76–84.CrossRef
66.
Phan BAP, Toth PP. Dyslipidemia in women: etiology and management. Int J Women's Health. 2014;6:185–94.
67.
Xiao C, Dash S, Morgantini C, Hegele RA, Lewis GF. Pharmacological targeting of the Atherogenic dyslipidemia complex: the next frontier in CVD prevention beyond lowering LDL cholesterol. Diabetes. 2016;65(7):1767–78.PubMedCrossRef
68.
69.
70.
Al-Goblan AS, Al-Alfi MA, Khan MZ. Mechanism linking diabetes mellitus and obesity. Diabetes, metabolic syndrome and obesity : targets and therapy. 2014;7:587–91.CrossRef
71.
Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113–32.PubMedCrossRef
72.
Murphy R, Carroll RW, Krebs JD. Pathogenesis of the metabolic syndrome: insights from monogenic disorders. Mediat Inflamm. 2013;2013:920214.CrossRef
Metadata
Title
Dynamic behavior of metabolic syndrome progression: a comprehensive systematic review on recent discoveries
Authors
Pezhman Bagheri
Davood Khalili
Mozhgan Seif
Abbas Rezaianzadeh
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2021
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-021-00716-7

Other articles of this Issue 1/2021

BMC Endocrine Disorders 1/2021 Go to the issue

Research

Erectile dysfunction and associated factors among diabetic patients at, Hawassa, Southern, Ethiopia

Research

The relationship between changes in serum myostatin and adiponectin levels in patients with obesity undergoing a weight loss program

Research article

Clinical risk score for central precocious puberty among girls with precocious pubertal development: a cross sectional study

Research

Prediction model for thyrotoxic atrial fibrillation: a retrospective study

Research article

Apolipoprotein A1 is negatively associated with male papillary thyroid cancer patients: a cross-sectional study of single academic center in China

Case report

Multiple endocrinopathies, hypercalcaemia and pancreatitis following combined immune checkpoint inhibitor use- case report and review of literature
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits